Poliomyelitis Vaccines Market Size, Share, Growth, And Industry Analysis, By Type (IPV and OPV), By Application (Research & Academic Laboratories, Pharmaceutical & Biotechnology Companies and Others), Regional Forecast To 2034

• 

  Request a Free sample to learn more about this report

POLIOMYELITIS VACCINES MARKET OVERVIEW

The global poliomyelitis vaccines market was valued at USD 0.83 billion in 2025 and is expected to grow to USD 0.86 billion in 2026, reaching USD 1.21 billion by 2035, with a projected CAGR of 4.1% during the forecast period.In 2024, Asia-Pacific held a dominant market position, capturing an approximately 23% share.

A highly contagious viral disease brought on by the poliovirus, poliomyelitis, usually known as polio, is prevented by poliomyelitis vaccines. Due to the polio virus's impact on the neurological system, paralysis, muscular weakness, and other severe consequences might occur. However, adults can also be affected by the illness, which primarily affects children under the age of 5. In order to prevent poliomyelitis, polio vaccines stimulate the immune system to develop antibodies that are specific to the poliovirus. Oral poliovirus vaccines (OPV) and inactivated poliovirus vaccines (IPV) are the two main vaccine kinds.

During the forecast period, there is anticipated to be significant increase in the market for poliomyelitis vaccines. Growing public knowledge of the benefits of poliomyelitis vaccination, ongoing clinical trials being conducted to treat the virus, and the purchase of vaccines by the WHO, UNICEF, and other governmental agencies to treat the infection will all boost the poliomyelitis market. Additional important influencing variables for the demand of the poliomyelitis market are improvements in treatment options and the availability of well-established healthcare facilities. COVID-19 also had a significant effect on the market's expansion.

KEY FINDINGS

COVID-19 IMPACT

Delay in Polio Eradication as Many Countries Redirected Their Health Infrastructure to Control the Pandemic

Global healthcare markets, especially those for poliomyelitis medication, had been significantly impacted by the COVID-19 pandemic. Despite the fact that the polio vaccine had been widely accessible for many years, the pandemic disrupted the regular immunization schedules, which caused a decline in demand for polio vaccines in some areas. In addition, the COVID-19 pandemic had taken focus off of and resources away from other health programmes, such as efforts to eradicate polio. There had been a delay in the elimination of polio as a result of many nations refocusing their resources and health infrastructure on controlling the pandemic.

LATEST TRENDS

Use of IPV Over OPV to Lessen the Likelihood of Outbreaks of VDPV

Inactivated polio vaccine (IPV) use is now the favored vaccine type, which is one of the newest trends in the poliomyelitis vaccines industry. Inactivated (killed) oral polio vaccine (IPV) is a form of polio vaccine that is thought to be safer than live attenuated oral polio vaccine (OPV), which contains weakened poliovirus. In order to completely eradicate polio, the World Health Organization (WHO) has been working towards this goal, and IPV is a crucial part of this endeavor. Many nations have switched from OPV to IPV, which is believed to lessen the likelihood of outbreaks of vaccine-derived poliovirus (VDPV). When the vaccine's weakened virus mutates and regains its capacity to spread disease, VDPV, an uncommon but dangerous adverse effect of OPV, may manifest. 

• According to UNICEF Supply, 816 million standalone IPV doses were procured from 2013–Dec 2024, and its 2023–2025 tender drew proposals from 8 manufacturers (with 5 already supplying WHO-prequalified IPV at the time).

• According to CDC’s MMWR, 74 cVDPV outbreaks were detected across 39 countries during Jan 2023–Jun 2024 (with 672 confirmed AFP cases), underscoring ongoing demand for OPV/nOPV2 for rapid SIAs.

Request a Free sample to learn more about this report

POLIOMYELITIS VACCINES MARKET SEGMENTATION

By Type Analysis

According to type, the market can be segmented into IPV and OPV

By Application Analysis

Based on application, the market can be divided into Research & Academic Laboratories, Pharmaceutical & Biotechnology Companies and Others

DRIVING FACTORS

Favorable Government Policies Implemented Fuel the Demand for the Vaccines

Numerous governments all across the world are putting policies into place and sponsoring initiatives to aid in the fight against polio and boost immunization rates. As an illustration, significant funding for the Global Polio Eradication Initiative (GPEI), a partnership between the WHO, UNICEF, Rotary International, the US Centers for Disease Control and Prevention (CDC), and the Bill and Melinda Gates Foundation, has come from governments, international organizations, and private donors to support polio eradication efforts. This financing fuels the demand for poliomyelitis vaccines by supporting vaccine manufacture, distribution, and immunization programmes in nations where polio is still prevalent or outbreaks occur.

• According to CDC, unvaccinated adults require a 3-dose IPV primary series (dose 2 at 1–2 months, dose 3 at 6–12 months after dose 2), while accelerated schedules for travellers specify 4 doses within defined intervals—directly translating into multi-dose course uptake.

• According to the U.S. FDA, IPOL (Sanofi Pasteur) is licensed for prevention of poliomyelitis caused by types 1, 2, and 3 in persons ≥6 weeks old—supporting continued IPV availability in major markets.

Increasing Research and Development Spending on Vaccines has Enhanced Market Demand

The rising demand for vaccinations and the possibility for sizable returns on investment have fueled a major surge in recent years in investment in vaccine research and development. The creation of new, more potent vaccinations as well as advancements in vaccine distribution and manufacturing have resulted from this expenditure. The demand for poliomyelitis vaccines has been boosted by the creation of novel polio vaccine formulations, such as the switch from oral to inactivated polio vaccine in the past few years.

RESTRAINING FACTORS

Lack of Raw Materials Needed to Produce the Vaccine is a Significant Restraint on Market Development

The scarcity of raw materials needed for vaccine manufacture is one of the major constraints limiting the poliomyelitis vaccines market growth. Virus strains are only a few of the raw materials needed to make polio vaccines; yet, these can be scarce or challenging to come by. The short-term availability of immunizations may be hampered by the lengthy and difficult polio vaccine production process. Another barrier to accessing immunizations in low and middle-income nations where polio is still prevalent or outbreaks occur is the high expense of vaccine production and delivery. Although government programmes and initiatives can assist solve this issue, it still poses a considerable barrier for many nations.

• According to UNICEF’s OPV market note, Sanofi Pasteur discontinued its OPV production (noted “production discontinued”), reducing legacy bOPV capacity and concentrating supply among fewer OPV manufacturers.

• Safety-driven programmatic changes reduce OPV use in high-income markets. According to the FDA IPOL insert, the U.S. documented 119 vaccine-associated paralytic polio (VAPP) cases 1980–1994 and switched to an all-IPV schedule in 1999, curbing OPV demand in certain segments

• Request a Free sample to learn more about this report

•  

POLIOMYELITIS VACCINES MARKET REGIONAL INSIGHTS

High Frequency of Polio Cases are Fueling the Need for the Vaccine in the Asia Pacific Region

Numerous nations in the Asia Pacific area are still reporting cases of polio, making it one of the regions that has been most negatively impacted by the disease. For instance, in 2020, Afghanistan and Pakistan accounted for the great majority of polio cases that were reported globally. The demand for poliomyelitis medicines in the area is fueled by the high frequency of polio. To promote polio eradication efforts and boost vaccination rates, many Asia Pacific nations have put policies into place and funded programmes. For instance, the Indian government has started a number of programmes to boost immunization rates and increase the country's access to polio vaccines. The demand for poliomyelitis immunizations in the area is being fueled in part by this government assistance. These are the key factors driving the dominance of Asia Pacific in the poliomyelitis vaccines market share.

KEY INDUSTRY PLAYERS

Key Players Focus on Acquisitions and Alliances to Enhance their Product Offerings

To increase their market presence and enhance their product offerings, market participants are forging partnerships and alliances. For instance, vaccine producers are collaborating with governmental bodies and international organizations to create and provide polio vaccines in low and middle-income nations. Additionally, market participants use mergers and acquisitions to improve their market positions and broaden their product lines. For instance, Sanofi announced in 2020 that it would purchase Takeda's vaccine division, which includes the manufacturer's line of polio vaccines.

• According to the U.S. FDA, IPOL covers 3 poliovirus types (1–3) and is indicated from 6 weeks of age, underpinning Sanofi’s status as the sole standalone IPV supplier in the U.S. market.

• Sanofi Pasteur: According to the U.S. FDA, IPOL covers 3 poliovirus types (1–3) and is indicated from 6 weeks of age, underpinning Sanofi’s status as the sole standalone IPV supplier in the U.S. market.

List of Top Poliomyelitis Vaccines Companies

• Sanofi (France)
• GSK (U.K.)
• Serum Institute (India)
• Tiantan Biological (China)
• IMBCA (Belgium)
• Panacea Biotec Ltd (India)
• Bio-Med (India)
• Halfkin Bio-Pharmaceuticals (India)

REPORT COVERAGE

This report covers the poliomyelitis vaccines market. The CAGR expected to be in during the forecast period, and also the USD value in 2024 and what it is expected to be in 2033. The effect COVID-19 had on the market in the beginning of the pandemic. The latest trends taking place in this industry. The factors that are driving this market as well as the factors that are restraining the growth of industry. The segmentation of this market based on type and applications. The region leading in the industry and why they will continue to do so during the forecast period. Further, the key market players, what all is being done by them to stay ahead of their competition as well as retain their market positions. All these details are covered in the report.